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Wegeners Granulomatosis (WG) is an ANCA-asso-
ciated vasculitis whose clinical triad involves the
upper respiratory airway, lungs and kidneys1. Skin
involvement has been observed in 14-47% of pa-
tients, either during or at onset of the disease and
may develop on unusual sites such as trunk, neck
and face2. 
Necrosis, granulomatous inflammation and vas-
culitis are histological hallmarks. 
Case-report: 60 year-old, diabetic, caucasian
male complaining of an eight months’ evolution
sero-hematic rhinorrhea, nasal obstruction and
crusting and a diffuse purplish vesicular rash (Figu -
res 1A, 1B), compatible with leucocytoclastic vas-
culitis; prednisolone 30 mg/day was then pres -
cribed. A paranasal polipoid mass was excised via
rhinoscopy (Figure 2), compatible with a chronic
inflammatory process, fibrosis and media thicke -
ning of small arteries.
Microhematuria (though normal renal biopsy),
polyarthralgia and bilateral recurrent episcleritis
were also noted. 
Chest X-ray, routine lab and immunological
workup (including ANCA) were normal. A small-
vessel vasculitis was diagnosed, probably WG. Due
to an exuberant skin involvement and refractoriety
to corticosteroids, clinical remission was achieved
with a 6 months‘ regimen pulsed cyclophospha -
mide (1g/m2/month) plus prednisolone (1 mg/kg/
/day). He relapsed under AZA maintenance thera-
py (250 mg/day), leading to the use of Mycophe-
nolate Mofetil (MMF- 3g/day), with sustained clini -
cal improvement (Figure 3).
This clinical case is particular in four keypoints:
an exuberant cutaneous involvement, resembling
pyoderma gangrenosum, a rare manifestation of
WG; the uncommon absence of pulmonary or renal
involvement (20% of cases)1; a negative c-ANCA,
possible in limited or inactive GW (65-70%), which,
adding to predominant skin and nasal affection,
Figure 1A and 1B. Exuberant cutaneous involvement
characterized by lesions in several stages-diffuse purplish
papules, pustules, vesicles, nodules, coalescent and 
sometimes necrotic (Pyoderma Gangrenosum-like)
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favors a limited WG diagnosis in our case; and a
sustained clinical remission under maintenance
with MMF, without toxicity.
A high rate of disease relapse (20-45%) after cy-
clophosphamide’s induction therapy prompts the
need for additional options10. Our choice was dic-
tated by MMF safety profile, case series reports3-7
and satisfactory experience in lupus and small-
vessel vasculitis. Nowack9 established MMF as well
tolerable and effective for maintenan ce therapy in
9 patients with WG and 2 patients with microscopic
polyangiitis, proving to be a pro mising, but still
poorly studied drug in vasculitis. 
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Figure 2. Polipoid mass in the paranasal sinuses 
(macroscopic aspect)
Figure 3. Clinical improvement regarding cutaneous 
involvement
